📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Glycomine

1.1 - Company Overview

Glycomine Logo

Glycomine

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of replacement therapies for rare diseases, including GLM101, a mannose-1-phosphate replacement therapy in clinical development for PMM2-CDG that delivers mannose-1-phosphate directly into cells to bypass PMM2 enzyme deficiency, and a Natural History Study, a longitudinal study to understand PMM2-CDG symptoms, progression, and clinical measures and biomarkers for the disease.

Products and services

  • Natural History Study: Longitudinal study characterizing PMM2-CDG symptoms and progression, delivering insights into clinical measures and biomarkers to understand disease course and support clinical evaluations
  • GLM101: Clinical-stage, mannose-1-phosphate replacement therapy for PMM2-CDG that delivers mannose-1-phosphate directly into cells, architected to bypass the PMM2 enzyme deficiency
  • Replacement Therapies for Rare Diseases R&D: Early-stage program developing replacement therapies for rare diseases, focusing company efforts on replacement therapeutic research and development

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Glycomine

Cydan Logo

Cydan

HQ: United States Website
  • Description: Provider of orphan drug accelerator services focused on identifying and de-risking compounds with therapeutic and commercial potential.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cydan company profile →
Avigen Logo

Avigen

HQ: United States Website
  • Description: Provider of biopharmaceutical R&D focused on treatments for neurological and other disorders. Develops the AV411 portfolio, including a phase II-stage lead drug compound and proprietary analogs, representing novel, non-opioid drugs for the treatment of pain.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Avigen company profile →
Essentialis Therapeutics Logo

Essentialis Therapeutics

HQ: United States Website
  • Description: Provider of orphan drug-focused pharmaceutical research and development, based in Carlsbad, in a clinical trial phase to develop breakthrough medicines for the treatment of rare metabolic diseases where there is increased mortality and risk of cardiovascular and endocrine.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Essentialis Therapeutics company profile →
Palvella Therapeutics Logo

Palvella Therapeutics

HQ: United States Website
  • Description: Provider of therapies for abandoned patient populations.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Palvella Therapeutics company profile →
Mitobridge Logo

Mitobridge

HQ: United States Website
  • Description: Provider of small molecule therapeutics that improve mitochondrial function to address diseases with high unmet need. Pipeline includes investigational candidates: ASP0367 for primary mitochondrial myopathies and Duchenne muscular dystrophy, ASP1128 for acute kidney injury, and an NAD+ modulation program targeting aging-related conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mitobridge company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Glycomine

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Glycomine

2.2 - Growth funds investing in similar companies to Glycomine

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Glycomine

4.2 - Public trading comparable groups for Glycomine

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Glycomine

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Glycomine

What does Glycomine do?

Glycomine is a provider of replacement therapies for rare diseases, including GLM101, a mannose-1-phosphate replacement therapy in clinical development for PMM2-CDG that delivers mannose-1-phosphate directly into cells to bypass PMM2 enzyme deficiency, and a Natural History Study, a longitudinal study to understand PMM2-CDG symptoms, progression, and clinical measures and biomarkers for the disease.

Who are Glycomine's competitors?

Glycomine's competitors and similar companies include Cydan, Avigen, Essentialis Therapeutics, Palvella Therapeutics, and Mitobridge.

Where is Glycomine headquartered?

Glycomine is headquartered in United States.

How many employees does Glycomine have?

Glycomine has 1,000 employees 🔒.

When was Glycomine founded?

Glycomine was founded in 2010 🔒.

What sector and industry vertical is Glycomine in?

Glycomine is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Glycomine

Who are the top strategic acquirers in Glycomine's sector and industry

Top strategic M&A buyers and acquirers in Glycomine's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Glycomine?

Top strategic M&A buyers groups and sectors for Glycomine include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Glycomine's sector and industry vertical

Which are the top PE firms investing in Glycomine's sector and industry vertical?

Top PE firms investing in Glycomine's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Glycomine's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Glycomine's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Glycomine's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Glycomine include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Glycomine's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Glycomine?

The key public trading comparables and valuation benchmarks for Glycomine include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Glycomine for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Glycomine with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Glycomine's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Glycomine with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Glycomine's' sector and industry vertical?

Access recent funding rounds and capital raises in Glycomine's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Glycomine